Based on real-time PCR (polymerase chain reaction) technology for disease detection and monitoring, the m2000, a fully automated system, represents the future of molecular diagnostics testing.

Abbott’s cutting-edge vascular product pipeline includes key development programs in next-generation drug-eluting stents.

Abbott scientists are studying compounds that target neuronal nicotinic receptors, which regulate key neurological functions, such as pain, mood and memory.

An Abbott scientist uses state-of-the-art tools to measure cellular responses to compounds in drug discovery.

Abbott scientists are developing new ways to manage diabetes better, diagnose diseases faster, preserve spine mobility and improve vascular care.

Diabetes Care

In diabetes care, we are developing new products that reduce the pain and inconvenience of blood glucose monitoring. This includes the FreeStyle Navigator Continuous Glucose Monitoring System, an investigational device that is designed to measure glucose levels every minute to allow patients to monitor their diabetes more closely. Also in development is an all-in-one glucose monitoring system that combines a glucose meter, test strips and lancing capabilities in one device.

Molecular Diagnostics

In diagnostics, we continue to make advancements in molecular testing, which have demonstrated advantages in detection, the selection of appropriate therapies and improved monitoring of disease progression. Included in our molecular diagnostics pipeline are real-time PCR (polymerase chain reaction) tests for infectious diseases and cancer.

Spine

We are committed to improving the standard of care with product innovations that correct abnormal spinal curvatures, including scoliosis, and address problems caused by traumatic spine injury. Additional technologies in the pipeline, such as the Wallis System, address motion preservation and dynamic stabilization of the spine — areas that are the future of spine care.

Vascular

Beyond our drug-eluting stent, Xience V, we have a robust portfolio of cutting-edge vascular development programs. Abbott is developing next-generation drug-eluting stents to address more complex vascular disease. We are the first to develop and evaluate in clinical trials a fully bioabsorbable drug-eluting coronary stent. We are also studying the role of vulnerable plaque, which could help identify and treat at-risk patients before a heart attack occurs.

Abbott’s pharmaceutical research and development is dedicated to discovering new treatments in therapeutic areas, such as cardiovascular disease, immunology, oncology, neuroscience and pain care and infectious diseases.

Cardiovascular

We are building on the success of our triglyceride-reducing fenofibrate, TriCor, with ABT-335, our next-generation fenofibrate, in late-stage trials. With AstraZeneca, we are codeveloping a statin-fenofibrate combination product with Crestor and TriCor or ABT-335 to target HDL, LDL and triglycerides. A new caplet formulation of Niaspan is under U.S. FDA review for primarily raising HDL, and we are working on a statin-combination opportunity with Niaspan called Simcor.

Immunology

In immunology, Abbott scientists continue to research and develop biologic treatments for autoimmune diseases. Humira continues in late-stage development for psoriasis, juvenile rheumatoid arthritis and ulcerative colitis. ABT-874 is a biologic being evaluated for psoriasis and Crohn’s disease.

Oncology

In our oncology pipeline, there are a number of breakthrough therapies being investigated to treat various forms of cancer. One in earlier stages, known as a Bcl-2 family inhibitor, is designed to kill tumors such as lymphomas. Another compound is designed to prevent DNA repair in cancer cells to stop the disease from progressing.

Neuroscience and Pain Care

In neuroscience and pain care, a controlled-release form of Vicodin is in Phase III development for moderate to moderately severe pain. Our scientists are also researching cutting-edge compounds for schizophrenia, Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) and pain.

Additional Therapies in Development

Flutiform is in Phase III development for asthma. We are also conducting early-stage infectious disease research to develop protease inhibitors for hepatitis C. This builds on our foundation in HIV where Abbott scientists discovered the protease inhibitor Kaletra.